

3-2018

# Drug Interaction Study Of Apixaban With Cyclosporine Or Tacrolimus: Results From A Phase I, Randomized, Open-Label, Crossover Study In Healthy Volunteers

Babar Bashir, MD

Thomas Jefferson University, [babar.bashir@jefferson.edu](mailto:babar.bashir@jefferson.edu)

Benjamin D. Tran, PharmD

Thomas Jefferson University, [benjamin.tran@jefferson.edu](mailto:benjamin.tran@jefferson.edu)

Santhi Mantravadi, MD

Thomas Jefferson University, [Santhi.Mantravadi@jefferson.edu](mailto:Santhi.Mantravadi@jefferson.edu)

Douglas F. Stickle, PhD

Thomas Jefferson University, [Douglas.Stickle@jefferson.edu](mailto:Douglas.Stickle@jefferson.edu)

Inna Chervoneva, PhD

Thomas Jefferson University, [Inna.Chervoneva@jefferson.edu](mailto:Inna.Chervoneva@jefferson.edu)

Follow this and additional works at: <http://jdc.jefferson.edu/petposters>

See next page for additional authors

 Part of the [Medical Pharmacology Commons](#)

[Let us know how access to this document benefits you](#)

## Recommended Citation

Bashir, MD, Babar; Tran, PharmD, Benjamin D.; Mantravadi, MD, Santhi; Stickle, PhD, Douglas F.; Chervoneva, PhD, Inna; and Kraft, MD, Walter K., "Drug Interaction Study Of Apixaban With Cyclosporine Or Tacrolimus: Results From A Phase I, Randomized, Open-Label, Crossover Study In Healthy Volunteers" (2018). *Department of Pharmacology and Experimental Therapeutics Posters*. 5. <http://jdc.jefferson.edu/petposters/5>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Posters by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

---

**Authors**

Babar Bashir, MD; Benjamin D. Tran, PharmD; Santhi Mantravadi, MD; Douglas F. Stickle, PhD; Inna Chervoneva, PhD; and Walter K. Kraft, MD

## Background

- Apixaban is a direct factor Xa inhibitor approved for treatment of venous thromboembolism (VTE)
- It is metabolized by the CYP3A4, and is a substrate to the permeability glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters
- The combined use of apixaban with a strong dual inhibitor of P-gp and CYP3A4 such as ketoconazole results in a 2-fold increase in apixaban exposure necessitating dose adjustment
- Cyclosporine and tacrolimus are indicated for prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants
- Cyclosporine is a weak inhibitor of CYP3A4 and potent inhibitor of both P-gp, BCRP
- Tacrolimus is believed to share overlapping inhibitor activity on these pathways but is considered a weaker inhibitor than cyclosporine
- Thus, concentrations of apixaban may potentially increase in transplant patients comedicated with calcineurin inhibitors


## Aims

- To determine the effect of 100mg cyclosporine administered daily for 3 days on the pharmacokinetic parameters of apixaban following coadministration of a single oral dose of 10 mg to healthy volunteers
- To determine the effect of 5mg tacrolimus administered daily for 3 days on the pharmacokinetic parameters of apixaban following coadministration of a single oral dose of 10 mg to healthy volunteers
- Pharmacokinetic (PK) parameters included  $AUC_{0-t_{last}}$ ,  $AUC_{0-\infty}$ ,  $C_{max}$ ,  $T_{max}$ , and apparent terminal  $t_{1/2}$

## Subjects and Methods

- 12 healthy adult males received three treatments in a crossover design (Figure 1)
- Apixaban plasma concentration was determined using a validated LC-MS/MS assay

Figure 1: Study Design



## Results

### Subject Demographics

Table 1. Subject Characteristics

	Number of Subjects (N=12), n (%)
<b>Male</b>	<b>12 (100.0)</b>
<b>Age (yr)</b>	<b>41</b>
<b>Range</b>	<b>25-54</b>
<b>BMI (Kg/m<sup>2</sup>), range</b>	<b>24-33</b>
<b>Race</b>	
<b>Black or African American</b>	<b>9 (75)</b>
<b>White</b>	<b>3 (25)</b>

### Apixaban Pharmacokinetic Interaction with Cyclosporine and Tacrolimus

- The concentration-time profile of 10 mg apixaban alone was compared to the concentration-time profile of 10 mg apixaban when cyclosporine (Figure 2A) or tacrolimus (Figure 2B) was coadministered
- The apixaban plasma concentration reached its peak ( $T_{max}$ ) at 2.5 hours postdose
- All subjects had no quantifiable predose concentrations of apixaban on day 1 of each treatment period. All subjects had quantifiable plasma apixaban concentrations up to 24 hours postdose
- Summary statistical comparison of PK parameters from subjects administered 10 mg apixaban alone compared to apixaban with cyclosporine and tacrolimus coadministration is presented in Table 2

Figure 2. Apixaban plasma concentration-time profile with Cyclosporine (A) and Tacrolimus (B)




Table 2. Summary Pharmacokinetic Parameters

PK Parameter	Apixaban alone	Cyclosporine DDI Study		Tacrolimus DDI Study	
	Geometric mean (90% CI)	Geometric mean (90% CI)	GMR (90% CI)	Geometric mean (90% CI)	GMR (90% CI)
$C_{max}$ (ng mL <sup>-1</sup> )	179 (147, 219)	257 (211, 311)	1.43 (1.12, 1.83)	157 (129, 191)	0.87 (0.67, 1.12)
$AUC_{0-t_{last}}$ (h ng mL <sup>-1</sup> )	1684 (1427, 1987)	2018 (1710, 2381)	1.20 (0.97, 1.48)	1318 (1117, 1555)	0.78 (0.63, 0.97)
$AUC_{0-\infty}$ (h ng mL <sup>-1</sup> )	1875 (1619, 2172)	2237 (1931, 2591)	1.19 (0.99, 1.44)	1448 (1251, 1678)	0.77 (0.64, 0.93)
$T_{max}$ (h)	2.5 [1, 4]	2.5 [1, 4]	-	2.5 [1, 4]	-
$t_{1/2}$ (h)	6.5 (3) [3.4, 12.6]	5.2 (1.8) [3.3, 10]	-	7.0 (1.9) [5, 11]	-

CI=confidence interval, DDI=drug-drug interaction, PK=pharmacokinetics, GMR=geometric least-squares mean ratio between treatments. Back-transformed least-squares mean and CI was derived from linear mixed-effects model performed on natural log-transformed values adjusting for the random effect of subject and the fixed effect of the sequence.

## Discussion

- The confidence interval for only  $C_{max}$ , but not  $AUC_{0-t_{last}}$  or  $AUC_{0-\infty}$ , lay completely above 1, indicating that overall apixaban exposure is unaffected when coadministered with cyclosporine
- The observed change in apixaban exposure with cyclosporine reflects the effect of combined inhibition of P-gp and BCRP transporter-mediated efflux as well as CYP3A4 metabolism
- The CI for both  $AUC_{0-t_{last}}$  and  $AUC_{0-\infty}$ , but not  $C_{max}$ , lay completely below 1, suggesting a small decrease in apixaban exposure when comedicated with tacrolimus
- The observed decrease in apixaban exposure with tacrolimus was unexpected. The inhibitory potency of tacrolimus on P-gp, BCRP transporters is not well characterized
- In the absence of potent inhibitory activity at the transporters, the coadministration of apixaban and tacrolimus, could potentially result in a competitive inhibition of transporter-mediated efflux, contributing to increased efflux and elimination of apixaban
- The change in apixaban exposure with cyclosporine or tacrolimus is not expected to meaningfully alter the safety and efficacy of apixaban based on the magnitude of other drug interactions listed in the product label

## Conclusion

- Multiple-dose administration of 100 mg cyclosporine or 5 mg tacrolimus daily with a single dose of 10 mg apixaban was generally well tolerated by the healthy subjects in the study
- Coadministration of cyclosporine or tacrolimus and apixaban had no clinically meaningful effect on the PK of apixaban
- Apixaban and cyclosporine or tacrolimus may be coadministered without dose adjustment

## Disclosures and Acknowledgements

This research was funded by ARISTA-USA grant administered by Bristol Myers-Squibb Co., Princeton, NJ., and Pfizer Inc., New York, NY. Babar Bashir was supported by an NIH institutional training grant (T32 GM008562)

The authors would like to thank:

- All the subjects who participated in this study
- Clinical research unit staff

## Contact Information

Babar Bashir, MD  
c/o Walter Kraft, MD  
Department of Pharmacology & Experimental Therapeutics  
Thomas Jefferson University  
1170 Main Bldg., 132 S. 10<sup>th</sup> St.  
Philadelphia, PA 19107-5244  
Phone: 215-955-9081  
Fax: 215-955-5681  
[walter.kraft@jefferson.edu](mailto:walter.kraft@jefferson.edu)